Contineum Therapeutics, INC.(CTNM),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

CTNM Contineum Therapeutics, INC.

Market Closed 12-19 16:00:00 EST

11.74

+0.35

+3.07%

盘后11.74

+0.000.00%

18:11 EST

High11.88	Low11.27	Vol436.88K
Open11.32	D1 Closing11.39	Amplitude5.36%
Mkt Cap428.86M	Tradable Cap282.05M	Total Shares36.53M
T/O5.12M	T/O Rate1.82%	Tradable Shares24.03M
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

Loading ...

{"stockData":{"symbol":"CTNM","market":"US","secType":"STK","nameCN":"Contineum Therapeutics, INC.","latestPrice":11.74,"timestamp":1766178000000,"preClose":11.39,"halted":0,"volume":436878,"hourTrading":{"tag":"盘后","latestPrice":11.74,"preClose":11.74,"latestTime":"18:11 EST","volume":6855,"amount":80478.75,"timestamp":1766185866527},"delay":0,"floatShares":24025000,"shares":36529449,"eps":-2.245934,"marketStatus":"Market Closed","change":0.35,"latestTime":"12-19 16:00:00 EST","open":11.32,"high":11.88,"low":11.27,"amount":5121427.738986,"amplitude":0.053556,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":-2.245934,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Mkt","tradingStatus":1,"beginTime":1766394000000},"marketStatusCode":7,"adr":0,"listingDate":1712289600000,"exchange":"NASDAQ","adjPreClose":11.39,"postHourTrading":{"tag":"盘后","latestPrice":11.74,"preClose":11.74,"latestTime":"18:11 EST","volume":6855,"amount":80478.75,"timestamp":1766185866527},"volumeRatio":0.7796169424602895,"impliedVol":2.185,"impliedVolPercentile":0.8701},"requestUrl":"/m/hq/s/CTNM/wiki","defaultTab":"wiki","newsList":[{"id":"2590579156","title":"Contineum Therapeutics Prices Upsized $90 Million Class A Share Offering","url":"https://stock-news.laohu8.com/highlight/detail?id=2590579156","media":"MT Newswires Live","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2590579156?lang=en_us&edition=fundamental","pubTime":"2025-12-12 16:19","pubTimestamp":1765527570,"startTime":"0","endTime":"0","summary":"Contineum Therapeutics  said late Thursday it priced its upsized underwritten public offering of about 7.3 million of class A shares at $12.25 apiece for gross proceeds of around $90 million.The company has granted underwriters a 30-day option to purchase up to an additional 1.1 million class A shares at the offering price.The offering is expected to close on Monday.","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["CTNM","BK4007"],"gpt_icon":0},{"id":"2590219565","title":"BRIEF-Contineum Therapeutics Prices Upsized $90 Million Public Offering At $12.25 Per Share","url":"https://stock-news.laohu8.com/highlight/detail?id=2590219565","media":"Reuters","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2590219565?lang=en_us&edition=fundamental","pubTime":"2025-12-12 11:26","pubTimestamp":1765509967,"startTime":"0","endTime":"0","summary":"BRIEF-Contineum Therapeutics Prices Upsized $90 Million Public Offering At $12.25 Per ShareDec 11 (Reuters) - Contineum Therapeutics Inc CTNM.O:CONTINEUM THERAPEUTICS ANNOUNCES PRICING OF UPSIZED $90.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251212:nTUA6TSXD6:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","CTNM"],"gpt_icon":0},{"id":"2590616521","title":"Contineum Therapeutics Announces Pricing of Upsized $90.0 Million Public Offering","url":"https://stock-news.laohu8.com/highlight/detail?id=2590616521","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2590616521?lang=en_us&edition=fundamental","pubTime":"2025-12-12 11:24","pubTimestamp":1765509842,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251212:nTUA6TSXD6:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["CTNM","BK4007"],"gpt_icon":0},{"id":"2590521615","title":"Contineum Therapeutics Inc - Offering of 7.3 Mln Shares at $12.25 per Share","url":"https://stock-news.laohu8.com/highlight/detail?id=2590521615","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2590521615?lang=en_us&edition=fundamental","pubTime":"2025-12-12 11:24","pubTimestamp":1765509842,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251212:nTUA6TSXD6:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["CTNM","BK4007"],"gpt_icon":0},{"id":"2590544343","title":"BUZZ-Contineum Therapeutics falls on planned $75 million share sale","url":"https://stock-news.laohu8.com/highlight/detail?id=2590544343","media":"Reuters","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2590544343?lang=en_us&edition=fundamental","pubTime":"2025-12-12 05:59","pubTimestamp":1765490360,"startTime":"0","endTime":"0","summary":"BUZZ-Contineum Therapeutics falls on planned $75 million share sale** Drug developer Contineum Therapeutics' CTNM.O shares fall 2.5% to $12.74 in extended trading** CTNM kicks off public offering of $75 million worth of shares** Goldman Sachs, Leerink Partners, Stifel, RBC Capital Markets and William Blair are joint book-running managers for proposed offering** Proceeds will be used to advance the development of its experimental drug, PIPE-791, and to fund research and development activities, among other purposes** CTNM has 29.2 million outstanding shares for $365.4 million market cap, per LSEG data** All seven brokerages covering the stock rate it \"buy\" or higher; median PT $22 — data compiled by LSEG** As of last close, CTNM down 10.8% YTD","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251211:nL6N3XH172:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU1868837300.USD","LU0251131958.USD","LU0106831901.USD","IE0034235188.USD","LU1868837136.USD","BK4504","LU1894683264.USD","LU2237443978.SGD","LU2471134796.USD","CTNM","IE0002270589.USD","BK4585","LU1894683348.USD","LU0345770308.USD","IE00BFXG1179.USD","LU2237443465.HKD","LU1668664300.SGD","LU1868836591.USD","LU1868836914.USD","BK4552","IE00B19Z3581.USD","BK4007","LU2237443382.USD","LU1791807156.HKD","LU0251142724.SGD","BK4207","LU0345770993.USD","LU0061475181.USD","LU0096364046.USD","LU2750360641.GBP","SF","IE0004091025.USD","MNSH","LU2471134879.HKD","LU2237443622.USD","LU0048573561.USD","BK4588","IE00BSNM7G36.USD","LU2750360997.AUD","LU2471134952.CNY","BK4516","BK4550","LU1868836757.USD","LU2237443895.HKD","LU2237443549.SGD","LU1804176565.USD","LU2237438978.USD","BK4127","BK4533","IE0004086264.USD"],"gpt_icon":0},{"id":"2590954172","title":"Contineum Therapeutics Inc - Phase 2 Trial for Pipe-791 Expected to Be Completed in June 2028 - SEC Filing","url":"https://stock-news.laohu8.com/highlight/detail?id=2590954172","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2590954172?lang=en_us&edition=fundamental","pubTime":"2025-12-12 05:45","pubTimestamp":1765489517,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251211:nFWN3XH0RO:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["CTNM","BK4007"],"gpt_icon":0},{"id":"2585383493","title":"Contineum Therapeutics Is Maintained at Outperform by Baird","url":"https://stock-news.laohu8.com/highlight/detail?id=2585383493","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2585383493?lang=en_us&edition=fundamental","pubTime":"2025-11-24 22:54","pubTimestamp":1763996040,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/CTNM/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  November 24, 2025 09:54 ET (14:54 GMT)","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CTNM"],"gpt_icon":0},{"id":"2585464603","title":"Contineum price target lowered to $14 from $16 at Baird","url":"https://stock-news.laohu8.com/highlight/detail?id=2585464603","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2585464603?lang=en_us&edition=fundamental","pubTime":"2025-11-24 20:35","pubTimestamp":1763987720,"startTime":"0","endTime":"0","summary":"Baird lowered the firm’s price target on Contineum (CTNM) to $14 from $16 and keeps an Outperform rating on the shares. The firm updated its model ...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/contineum-price-target-lowered-to-14-from-16-at-baird-thefly?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/contineum-price-target-lowered-to-14-from-16-at-baird-thefly?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["CTNM","BK4007"],"gpt_icon":0},{"id":"2585276123","title":"Contineum Shares Fall After Phase 2 PIPE-307 Trial Fails to Meet Efficacy Goals in Multiple Sclerosis","url":"https://stock-news.laohu8.com/highlight/detail?id=2585276123","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2585276123?lang=en_us&edition=fundamental","pubTime":"2025-11-22 04:18","pubTimestamp":1763756289,"startTime":"0","endTime":"0","summary":"Contineum Therapeutics  shares were down about 10% in recent Friday trading after the company said late Thursday that its phase 2 trial of PIPE-307, in development for the treatment of patients with relapsing-remitting multiple sclerosis, failed to meet its primary and secondary efficacy goals.The company said PIPE-307 showed an acceptable safety and tolerability profile. Contineum said it is continuing to analyze exploratory endpoints and plans to present the full dataset at a future medical meeting.The company said it remains committed to pursuing novel therapies for patients with inflammatory and fibrotic diseases.Price: 10.93, Change: -1.29, Percent Change: -10.56","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK4007","CTNM","PIPE"],"gpt_icon":0},{"id":"2585490181","title":"Contineum Therapeutics Is Maintained at Outperform by RBC Capital","url":"https://stock-news.laohu8.com/highlight/detail?id=2585490181","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2585490181?lang=en_us&edition=fundamental","pubTime":"2025-11-21 22:45","pubTimestamp":1763736300,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/CTNM/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  November 21, 2025 09:45 ET (14:45 GMT)","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CTNM"],"gpt_icon":0},{"id":"2585143314","title":"Contineum Therapeutics: Undervalued Potential in IPF with PIPE-791 Amidst PIPE-307 Setback","url":"https://stock-news.laohu8.com/highlight/detail?id=2585143314","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2585143314?lang=en_us&edition=fundamental","pubTime":"2025-11-21 20:55","pubTimestamp":1763729718,"startTime":"0","endTime":"0","summary":"Debanjana Chatterjee, an analyst from JonesTrading, reiterated the Buy rating on Contineum Therapeutics, Inc. Class A. The associated price target ...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/ratings/contineum-therapeutics-undervalued-potential-in-ipf-with-pipe-791-amidst-pipe-307-setback-ratings?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/ratings/contineum-therapeutics-undervalued-potential-in-ipf-with-pipe-791-amidst-pipe-307-setback-ratings?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4007","PIPE","CTNM"],"gpt_icon":0},{"id":"2585102371","title":"Contineum Therapeutics Inc : Jonestrading Cuts Target Price to $22 From $25","url":"https://stock-news.laohu8.com/highlight/detail?id=2585102371","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2585102371?lang=en_us&edition=fundamental","pubTime":"2025-11-21 20:18","pubTimestamp":1763727494,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251121:nFWN3WX0GJ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["CTNM","BK4007"],"gpt_icon":0},{"id":"2585635110","title":"Contineum Therapeutics, Inc. Class A (CTNM) Gets a Buy from RBC Capital","url":"https://stock-news.laohu8.com/highlight/detail?id=2585635110","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2585635110?lang=en_us&edition=fundamental","pubTime":"2025-11-21 19:56","pubTimestamp":1763726193,"startTime":"0","endTime":"0","summary":"In a report released yesterday, Brian Abrahams from RBC Capital maintained a Buy rating on Contineum Therapeutics, Inc. Class A, with a price targe...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/contineum-therapeutics-inc-class-a-ctnm-gets-a-buy-from-rbc-capital-blurbs-2?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/contineum-therapeutics-inc-class-a-ctnm-gets-a-buy-from-rbc-capital-blurbs-2?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["LU0708994859.HKD","LU0310800379.SGD","LU1267930573.SGD","BK4007","LU0029864427.USD","LU0128525929.USD","BK4207","CTNM"],"gpt_icon":0},{"id":"2585848110","title":"Positive Outlook on Contineum Therapeutics Despite Setbacks, Driven by PIPE-791’s Potential in IPF","url":"https://stock-news.laohu8.com/highlight/detail?id=2585848110","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2585848110?lang=en_us&edition=fundamental","pubTime":"2025-11-21 19:55","pubTimestamp":1763726151,"startTime":"0","endTime":"0","summary":"Stifel Nicolaus analyst Paul Matteis has maintained their bullish stance on CTNM stock, giving a Buy rating yesterday. Paul Matteis has given his B...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/ratings/positive-outlook-on-contineum-therapeutics-despite-setbacks-driven-by-pipe-791s-potential-in-ipf-ratings?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/ratings/positive-outlook-on-contineum-therapeutics-despite-setbacks-driven-by-pipe-791s-potential-in-ipf-ratings?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["PIPE","CTNM","BK4007"],"gpt_icon":0},{"id":"2585117561","title":"RBC Lowers Price Target on Contineum Therapeutics to $22 From $25, Keeps Outperform, Speculative Risk","url":"https://stock-news.laohu8.com/highlight/detail?id=2585117561","media":"MT Newswires Live","labels":["express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2585117561?lang=en_us&edition=fundamental","pubTime":"2025-11-21 19:32","pubTimestamp":1763724747,"startTime":"0","endTime":"0","summary":"Contineum Therapeutics (CTNM) has an average rating of buy and mean price target of $22.83, according to analysts polled by FactSet.(MT Newswires covers equity, commodity and economic research from ma","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate","earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["CTNM"],"gpt_icon":0},{"id":"2585166553","title":"Stocks to Watch: Contineum, Gap Inc., Geospace Technologies","url":"https://stock-news.laohu8.com/highlight/detail?id=2585166553","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2585166553?lang=en_us&edition=fundamental","pubTime":"2025-11-21 07:31","pubTimestamp":1763681460,"startTime":"0","endTime":"0","summary":"Contineum Therapeutics said its drug designed to treat multiple sclerosis didn't meet its trial endpoints. The stock fell 12%, to $10.75, in after-hours trading Thursday.Gap Inc. raised its fiscal-year sales outlook after its three main brands logged same-store sales growth. Shares advanced 4.8%, to $24.16, after the bell.Geospace Technologies said oil volatility and less offshore exploration resulted in an 11% drop in quarterly sales. The stock declined 11%, to $15.35.","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4179","CTNM","BK4007","GAP","BK4585","GEOS","BK4094"],"gpt_icon":0},{"id":"2585657811","title":"Optimistic Buy Rating for Contineum Therapeutics Amid Promising PIPE-791 Developments","url":"https://stock-news.laohu8.com/highlight/detail?id=2585657811","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2585657811?lang=en_us&edition=fundamental","pubTime":"2025-11-21 07:05","pubTimestamp":1763679930,"startTime":"0","endTime":"0","summary":"William Blair analyst Myles Minter has reiterated their bullish stance on CTNM stock, giving a Buy rating on November 6. Myles Minter has given his...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/ratings/optimistic-buy-rating-for-contineum-therapeutics-amid-promising-pipe-791-developments-ratings?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/ratings/optimistic-buy-rating-for-contineum-therapeutics-amid-promising-pipe-791-developments-ratings?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["CTNM","PIPE"],"gpt_icon":0},{"id":"2585168067","title":"Contineum Therapeutics MS Treatment Fails to Meet Trial Endpoints","url":"https://stock-news.laohu8.com/highlight/detail?id=2585168067","media":"Dow Jones","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2585168067?lang=en_us&edition=fundamental","pubTime":"2025-11-21 06:07","pubTimestamp":1763676420,"startTime":"0","endTime":"0","summary":"Contineum Therapeutics said a trial of its treatment for relapsing-remitting multiple sclerosis didn't meet its primary or secondary efficacy endpoints.The San Diego biopharmaceutical company said Thursday that topline data from a phase 2 trial of PIPE-307 showed no significant change in patients' binocular 2.5% low contrast letter acuity.The company plans to interrogate the trial data related to its exploratory endpoints.\"We intend to learn from these data and remain committed to pursuing novel therapies for patients with inflammatory and fibrotic diseases,\" Chief Medical Officer Timothy Watkins said.Shares slid 15%, to $10.33, in after-hours trading.","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":"Contineum Therapeutics MS Treatment Fails to Meet Trial Endpoints","news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU2271345857.HKD","LU0158827948.USD","IE00BKVL7J92.USD","LU0106831901.USD","LU0314104364.USD","LU1791710400.SGD","LU1720051017.SGD","LU0795875169.SGD","LU0882574139.USD","LU1989772840.SGD","LU0098860793.USD","LU0234570918.USD","LU1548497426.USD","LU0795875086.SGD","LU0557290698.USD","LU0971096721.USD","LU0158827781.USD","LU2023251221.USD","LU2347655156.SGD","IE00BZ1G4Q59.USD","LU1720051108.HKD","LU2089283258.USD","LU1732799900.SGD","BK4504","LU1244550494.USD","LU0225283273.USD","CTNM","LU0528227936.USD","BK4516","LU1244550221.USD","LU2028103732.USD","BK4007","LU2357305700.SGD","BK4581","LU2111349929.HKD","LU1244550577.SGD","LU1791710582.SGD","LU0912757837.SGD","LU1074936037.SGD","LU0320765646.SGD","LU0106261372.USD","LU0267386448.USD","LU1668664300.SGD","LU2133065610.SGD","LU0006306889.USD","LU1989772923.USD","LU1732800096.USD","BK4588","LU1162221912.USD","LU1363072403.SGD"],"gpt_icon":0},{"id":"2585168593","title":"BRIEF-Contineum Therapeutics Reports Topline Data From Its Phase 2 Pipe-307 Vista Trial For The Treatment Of Relapsing-Remitting Multiple Sclerosis","url":"https://stock-news.laohu8.com/highlight/detail?id=2585168593","media":"Reuters","labels":["dataReport","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2585168593?lang=en_us&edition=fundamental","pubTime":"2025-11-21 05:43","pubTimestamp":1763674984,"startTime":"0","endTime":"0","summary":"BRIEF-Contineum Therapeutics Reports Topline Data From Its Phase 2 Pipe-307 Vista Trial For The Treatment Of Relapsing-Remitting Multiple Sclerosis Nov 20 (Reuters) - Contineum Therapeutics Inc CTNM.O","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251120:nTUA6PCSB0:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CTNM","BK4007"],"gpt_icon":0},{"id":"2585814168","title":"Contineum Therapeutics Reports Phase 2 Trial Results","url":"https://stock-news.laohu8.com/highlight/detail?id=2585814168","media":"TIPRANKS","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2585814168?lang=en_us&edition=fundamental","pubTime":"2025-11-21 05:31","pubTimestamp":1763674290,"startTime":"0","endTime":"0","summary":"Contineum Therapeutics, Inc. Class A ( ($CTNM) ) has shared an update. On November 20, 2025, Contineum Therapeutics reported topline data from its ...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/contineum-therapeutics-reports-phase-2-trial-results?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/contineum-therapeutics-reports-phase-2-trial-results?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4007","CTNM"],"gpt_icon":0}],"profile":{"websiteUrl":"http://www.contineum-tx.com","stockEarnings":[{"period":"1week","weight":0.0095},{"period":"1month","weight":-0.0555},{"period":"3month","weight":-0.0608},{"period":"6month","weight":1.4664},{"period":"1year","weight":-0.1206},{"period":"ytd","weight":-0.1986}],"compareEarnings":[{"period":"1week","weight":-0.0017},{"period":"1month","weight":0.0271},{"period":"3month","weight":0.0254},{"period":"6month","weight":0.1452},{"period":"1year","weight":0.1612},{"period":"ytd","weight":0.1613}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"exchange":"NASDAQ","name":"Contineum Therapeutics, INC.","nameEN":"Contineum Therapeutics, INC."},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.35.12","shortVersion":"4.35.12","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Contineum Therapeutics, INC.(CTNM),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest Contineum Therapeutics, INC.(CTNM) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"Contineum Therapeutics, INC.,CTNM,Contineum Therapeutics, INC.股票,Contineum Therapeutics, INC.股票老虎,Contineum Therapeutics, INC.股票老虎国际,Contineum Therapeutics, INC.行情,Contineum Therapeutics, INC.股票行情,Contineum Therapeutics, INC.股价,Contineum Therapeutics, INC.股市,Contineum Therapeutics, INC.股票价格,Contineum Therapeutics, INC.股票交易,Contineum Therapeutics, INC.股票购买,Contineum Therapeutics, INC.股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Contineum Therapeutics, INC.(CTNM),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest Contineum Therapeutics, INC.(CTNM) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}

Introduction